US FDA requires boxed warning and REMS for botulinum toxin products
This article was originally published in SRA
Prompted by reports of serious adverse events, the US Food and Drug Administration is requiring safety labelling changes, including a boxed warning, and a Risk Evaluation and Mitigation Strategy, for all botulinum toxin products1. Manufacturers are required to submit the requested safety labelling changes, including the boxed warning and a Medication Guide, to the FDA by the end of May, or to provide a reason why they do not believe such changes are necessary.
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?